Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Period	fcf
2015-12-31	-$15.77M
2016-12-31	-$21.31M
2017-12-31	-$14.69M
2018-12-31	-$3.09M
2019-12-31	-$9.80M
2020-12-31	$14.95M
2021-12-31	$21.13M
2022-12-31	$10.09M
2023-12-31	$7.80M
2024-12-31	-$5.81M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VCEL	$33.82	+1.47%	0.28M
3
4
5

Vericel Corporation (VCEL) Free Cash Flow

Free Cash Flow Data

Get Vericel Corporation Data in Excel

More VCEL Financial Data